Clinical Trials
Below are current clinical trials.
273 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
The pupose of this study is to evaluate near-patient methods, including both point of care (POC) and patient-performed testing.
-
Rochester, Minn.
The purpose of this study is to understand how transitioning to telework due to COVID-19 impacts employee satisfaction in one health care facility and how select non-clinical employees describe their experiences after transitioning from an in-person work environment to telework.
-
Rochester, Minn.
The purpose of this study is to look at the use of a novel biofeedback-assisted meditation device when used during the day to provide mindfulness training if it can increase calm state brain activity in post-Covid patients.
-
Rochester, Minn.
The purpose of this study is to evaluate the immune response of healthy individuals to the 2017-2018 seasonal flu vaccine.
-
Rochester, Minn.
We purpose of this study is to evaluate the diagnosis accuracy of the Controlled Attenuation Parameter (CAP) measured by FibroScan® (both with M and XL probes) in all patients who are undergoing liver biopsy for any liver disease.
-
Rochester, Minn.
This study is designed to determine if individual patients with HIV infection have been cured of the infection. To do this, antiretroviral therapy is discontinued under close medical supervision and the patient monitored over time for reactivation of infection.
-
Jacksonville, Fla.
Stage A: To evaluate the safety and efficacy of the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in adult patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of infection by the Zika virus (ZIKV), and the risk of asymptomatic infection among qualified blood donors is recognized. Besides the reduction of risk of transfusion transmitted ZIKV, the intent of the study is also to reduce the risk of transfusion-transmitted infections (TTI) in general, including transfusion related sepsis and other emerging or concurrent endemic pathogens (e.g. Dengue and Chikungunya), and to reduce the risk of TA-GVHD. As part of this treatment use study, additional data will be provided on the safety of INTERCEPT-treated RBCs (IBS RBCs) supplied for routine clinical transfusion practice.
-
Rochester, Minn.
The purpose of this study is to determine if an investigational treatment (Maribavir) is safe and effective in treating transplant recipient patients with cytomegalovirus (CMV) infections that are refractory or resistant to treatment.
-
Rochester, Minn.
The aim of this study is to identify difficult to diagnose microbial pathogens causing infections using blood or urine for identification of bacteria, viruses, fungi or parasites that are not detectable or are difficult to detect using current diagnostic techniques.
-
Jacksonville, Fla.
The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections.